These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 12090329)

  • 1. Past, present and future of erythropoietin use in the elderly.
    de Francisco AL; Fernandez Fresnedo G; Rodrigo E; Piñera C; Heras M; Palomar R; Ruiz JC; Arias M
    Int Urol Nephrol; 2002; 33(1):187-93. PubMed ID: 12090329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
    Dimković N
    Med Pregl; 2001; 54(5-6):235-40. PubMed ID: 11759218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin.
    Moreno F; Aracil FJ; Pérez R; Valderrábano F
    Am J Kidney Dis; 1996 Apr; 27(4):548-56. PubMed ID: 8678066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost-effectiveness analysis of anemia screening before erythropoietin in patients with end-stage renal disease.
    Hutchinson FN; Jones WJ
    Am J Kidney Dis; 1997 May; 29(5):651-7. PubMed ID: 9159297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoietin in heart failure.
    Silverberg DS; Wexler D; Blum M; Iaina A; Sheps D; Keren G; Schwartz D
    Semin Nephrol; 2005 Nov; 25(6):397-403. PubMed ID: 16298262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients.
    Drüeke TB; Bárány P; Cazzola M; Eschbach JW; Grützmacher P; Kaltwasser JP; Macdougall IC; Pippard MJ; Shaldon S; van Wyck D
    Clin Nephrol; 1997 Jul; 48(1):1-8. PubMed ID: 9247771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy of recombinant erythropoietin on the quality of life in patients over 60 years of age undergoing hemodialysis].
    Russo GE; Giusti S; Vitaliano E; Caramiello MS; Maurici M; De Marco CM; Pennacchia M; D'Auria F; Bonello M; Bruno C; Marigliano V
    Clin Ter; 1997 Mar; 148(3):89-93. PubMed ID: 9377845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.
    Pérez-Oliva JF; Casanova-González M; García-García I; Porrero-Martín PJ; Valenzuela-Silva CM; Hernández-Montero T; Lagarde-Ampudia M; Casanova-Kutsareva Y; Avila-Albuerne Y; Vargas-Batista A; Bobillo-López H; Herrera-Valdés R; López-Saura PA;
    BMC Nephrol; 2005 May; 6():5. PubMed ID: 15910687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of anemia correction on cardiovascular disease in end-stage renal disease.
    Murphy ST; Parfrey PS
    Semin Nephrol; 2000 Jul; 20(4):350-5. PubMed ID: 10928337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous iron supplementation in end-stage renal disease patients.
    Matzke GR
    Am J Kidney Dis; 1999 Mar; 33(3):595-7. PubMed ID: 10070926
    [No Abstract]   [Full Text] [Related]  

  • 11. Iron requirements in hemodialysis.
    Sargent JA; Acchiardo SR
    Blood Purif; 2004; 22(1):112-23. PubMed ID: 14732819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic fatty liver disease (NAFLD)--is it a new marker of hyporesponsiveness to recombinant human erythropoietin in patients that are on chronic hemodialysis?
    Orlic L; Mikolasevic I; Lukenda V; Racki S; Stimac D; Milic S
    Med Hypotheses; 2014 Dec; 83(6):798-801. PubMed ID: 25456789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombocytosis in EPO-treated dialysis patients may be mediated by EPO rather than iron deficiency.
    Vaziri ND
    Am J Kidney Dis; 2009 May; 53(5):733-6. PubMed ID: 19303685
    [No Abstract]   [Full Text] [Related]  

  • 14. Iron metabolism indices for early prediction of the response and resistance to erythropoietin therapy in maintenance hemodialysis patients.
    Tarng DC; Chen TW; Huang TP
    Am J Nephrol; 1995; 15(3):230-7. PubMed ID: 7618648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron overload in the erythropoietin era.
    Robbins KC
    Nephrol Nurs J; 2000 Apr; 27(2):227-31. PubMed ID: 11111550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of folate deficiency on erythropoietin resistance in pediatric and adolescent patients on chronic dialysis.
    Bamgbola OF; Kaskel F
    Pediatr Nephrol; 2005 Nov; 20(11):1622-9. PubMed ID: 16133045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron in the treatment of anemia in dialysis patients: an important support to erythropoietin.
    Gallieni M
    Int J Artif Organs; 1998 Nov; 21(11):681-6. PubMed ID: 9894741
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
    Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
    Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of iron treatment in the optimization of the use of erythropoietin (EPO) in hemodialyzed patients].
    Cigarrán S; Barril G
    Nefrologia; 2001; 21(5):510-1. PubMed ID: 11795024
    [No Abstract]   [Full Text] [Related]  

  • 20. Adjusting i.v. iron and EPO doses in patients on hemodialysis prior to continuing surgery: can we protect our patients education from iron-deficiency anemia?
    Deaver K; Bennington L
    Nephrol Nurs J; 2006; 33(4):430-7; quiz 438. PubMed ID: 17002001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.